Gsk (GSK) Payables (2009 - 2026)
Gsk (GSK) posted quarterly Payables of -$25.0 billion for Q2 2026, down 11.08% year-over-year from -$28.1 billion in Q2 2025, and up 4.31% quarter-over-quarter from -$26.1 billion in Q1 2026.
Gsk (GSK) Payables (2009 - 2026) Analysis & Trends
Gsk's Payables history runs 18 years deep, the most recent figure standing at -$25.0 billion for Q2 2026.
- In Q2 2026, Payables fell 11.08% year-over-year to -$25.0 billion; the TTM figure through Jun 2026 stood at -$25.0 billion (down 11.08% YoY), while the FY2025 annual figure was -$24.3 billion, down 207.58% from the prior year.
- Payables for Q2 2026 stood at -$25.0 billion, up from -$26.1 billion in the prior quarter.
- The five-year high for Payables was $23.7 billion in Q4 2022, with the low at -$26.1 billion in Q1 2026.
- The 5-year median for Payables is -$22.3 billion (2022), against an average of -$14.5 billion.
- The sharpest annual moves came in 2022 and 2023: Payables soared 81.62% in 2022, then slumped 399.84% in 2023.
- Gsk's Payables stood at $23.7 billion in 2022, then decreased by 2.41% to $23.1 billion in 2023, then dropped by 2.18% to $22.6 billion in 2024, then plunged by 192.01% to -$20.8 billion in 2025, then decreased by 20.05% to -$25.0 billion in 2026.
- Business Quant data shows GSK's Payables at -$25.0 billion in Q2 2026, -$26.1 billion in Q1 2026, and -$20.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 20.92 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 5.96 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 7.03 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -25.00 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.00 Bn |
| Mar 31, 2026 | -26.13 Bn |
| Dec 31, 2025 | -20.83 Bn |
| Sep 30, 2025 | -25.01 Bn |
| Jun 30, 2025 | -22.51 Bn |
| Mar 31, 2025 | -21.55 Bn |
| Dec 31, 2024 | 22.63 Bn |
| Sep 30, 2024 | -22.33 Bn |
| Jun 30, 2024 | -22.23 Bn |
| Mar 31, 2024 | -21.87 Bn |
| Dec 31, 2023 | 23.14 Bn |
| Sep 30, 2023 | -25.87 Bn |
| Jun 30, 2023 | -24.87 Bn |
| Mar 31, 2023 | -22.52 Bn |
| Dec 31, 2022 | 23.71 Bn |
| Sep 30, 2022 | -22.28 Bn |
| Jun 30, 2022 | -22.84 Bn |
| Mar 31, 2022 | -4.51 Bn |
| Dec 31, 2021 | 28.52 Bn |
| Sep 30, 2021 | -27.71 Bn |